Unfortunately the subsequent 2b trial was closed after an interim analysis. That being said the survival with this dosing schema of sbrt are excellent compared to historical outcomes, which hopefully continues to build the role for rt in this tough disease using our best technology.
Thanks - did not realize that. Have to say, not inconsistent with this data and the HN data. Bench to bedside is a long, tough road. Agree that the dosing of SBRT from this study remains promising.
It only happened in the last 6 weeks. The preclinical effect from that drug was very interesting in that it really only seemed to have an impact on radio sensitivity as the dose approached 10Gy in vitro, which typically translates to even higher doses in vivo. Thus their reasonable choice of 50Gy/5 fractions in patients may have been doomed to fail. But it would also be very difficult to accrue to a trial attempting 42Gy/3 fractions without mandatory MRI guidance given the risk of grade 4/5 toxicity if the drug doesn't protect as much as they think...
Unfortunately the subsequent 2b trial was closed after an interim analysis. That being said the survival with this dosing schema of sbrt are excellent compared to historical outcomes, which hopefully continues to build the role for rt in this tough disease using our best technology.
Thanks - did not realize that. Have to say, not inconsistent with this data and the HN data. Bench to bedside is a long, tough road. Agree that the dosing of SBRT from this study remains promising.
It only happened in the last 6 weeks. The preclinical effect from that drug was very interesting in that it really only seemed to have an impact on radio sensitivity as the dose approached 10Gy in vitro, which typically translates to even higher doses in vivo. Thus their reasonable choice of 50Gy/5 fractions in patients may have been doomed to fail. But it would also be very difficult to accrue to a trial attempting 42Gy/3 fractions without mandatory MRI guidance given the risk of grade 4/5 toxicity if the drug doesn't protect as much as they think...